Chemotherapeutic Strategies for Advanced NSCLC in the Era of Personalized Medicine: A Focus on Platinum-Refractory Disease

This activity contains:

  • CME/CNE-Certified Live Grand Rounds and Webinars
  • Downloadable Slide Deck (a non-certified educational resource, scheduled release date of December 2017)

Purpose
The goal of this activity is to provide clinicians with the latest advances in the treatment of patients with advanced NSCLC that do not have an actionable mutation target and have progressed on or after prior platinum-based therapy.

Activity Overview
Lung cancer continues to be the leading cause of cancer death in the United States, accounting for 27% of all cancer deaths in males and 25% in females.

Despite the importance of genomic profiling and the advent of targeted therapies, chemotherapeutic strategies remain a cornerstone treatment for patients with advanced non–small cell lung cancer (NSCLC). This includes those patients without actionable mutations in the treatment-naive setting as well as patients with NSCLC that progresses on frontline platinum therapy, and those patients with genetic alterations who develop resistance to targeted therapies.

This activity will highlight the ever-present role of chemotherapeutic strategies specifically in the platinum-refractory setting and its role in improving outcomes including survival and quality of life, including available treatment options, selecting the most appropriate therapy for these patients, and how clinical and biomarker data may inform selection of available treatment options.

Activity Agenda

  • Activity Overview (5 min)
  • The Importance of Mutational Testing Toward Identifying Patients Without Actionable Oncogenic Driver Mutations (10 min)
  • Selecting Optimal Therapy for Patients Without an Actionable Oncogenic Driver Mutation (25 min)
  • Practical Application Cases and Discussion Points (15 min)
  • Concluding Remarks and Audience Q&A (5 min)

Target Audience

This activity is intended for medical oncologists, thoracic oncologists, pulmonologists, pathologists, oncology nurses, and other healthcare professionals.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Use biomarker testing and patient characteristics to identify which patients have an actionable mutation target vs. those that do not to guide treatment selection for NSCLC
  • Analyze treatment options for patients with advanced NSCLC that does not have an actionable mutation target and has progressed on or after prior platinum-based therapy, and select appropriate treatment for these patients
  • Assess emerging combination approaches in clinical trials for the treatment of NSCLC that has progressed on or after platinum-based therapy
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Attendance
Course opens: 
08/14/2017
Course expires: 
12/28/2018
Cost:
$0.00
Rating: 
4

Chairperson

Benjamin Levy, MD
Assistant Professor, Johns Hopkins University School of Medicine
Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Medical Director, Thoracic Oncology Program, SKCCC at Sibley Memorial
Washington, DC

Faculty Speakers

Joshua Bauml, MD
Assistant Professor of Medicine 
Perelman School of Medicine at University of Pennsylvania
Philadelphia, PA

David S. Ettinger, MD, FACP, FCCP
Alex Glass Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

Stephen V. Liu, MD
Assistant Professor of Medicine
Georgetown University
Washington, DC
Karen L. Reckamp, MD, MS
Associate Professor of Medicine
City of Hope Comprehensive Cancer Center
Duarte, CA
Jonathan W. Riess, MD, MS
Assistant Professor 
UC Davis School of Medicine
Sacramento, CA
Mark A. Socinski, MD
Executive Medical Director
Florida Hospital Cancer Institute
Orlando, FL
Heather Wakelee, MD
Associate Professor of Medicine
The Stanford University Medical Center
Stanford, CA
Jared Weiss, MD
Associate Professor of Medicine and Section Chief
Thoracic Head and Neck Oncology
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC 


Continuing Education
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


 


Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.

Iowa Board of Nursing
AXIS is Iowa Board of Nursing approved provider number 371. This program is awarded 1.0 contact hour.

Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or PresenterReported Financial Relationship
Benjamin Levy, MDBenjamin Levy, MD, reported a financial interest/relationship or affiliation in the form of Consultant, AstraZeneca Pharmaceuticals LP; Celgene Corp; Eli Lilly and Co; Genentech, Inc; Merck & Co, Inc; Bristol-Myers Squibb Co.
Joshua Bauml, MDJoshua Bauml, MD, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Boehringer Ingelheim; Guardant Health, Inc; Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Celgene Corp; Merck & Co, Inc; Genentech, Inc; Contracted research, Merck & Co, Inc; Bayer HeatlhCare, Inc; Novartis Pharmaceuticals Corp; Incyte Corp.

David S. Ettinger, MD, FACP, FCCP

David S. Ettinger, MD, FACP, FCCP, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, AbbVie; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb Co; Celgene Corp; Eli Lilly and Co; EMD Serono, Inc; Genentech, Inc; Golden Biotech Corp; Guardant Health, Inc; Helsinn Therapeutics (US) Inc; Herron Therapeutics; Trovgene, Inc.
Stephen V. Liu, MDStephen V. Liu, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Genentech, Inc; Boehringer Ingelheim; Pfizer, Inc; Ariad Pharmaceuticals, Inc; Celgene Corp; Eli Lilly and Co; Taiho Pharmaceutical Co, Ltd; Bristol-Myers Squibb Co; Contracted research, Genentech, Inc; Pfizer, Inc; Threshold Pharmaceuticals; Clovis Oncology; Corvus; Esanex Inc; Bayer Pharmaceuticals Corp; OncoMed Pharmaceuticals; Ignyta; Merck & Co, Inc; MedImmune; Lycera
Karen L. Reckamp, MD, MS

Karen L. Reckamp, MD, MS reported a financial interest/relationship or affiliation in the form of Consultant, Amgen, Inc.; Takeda/Ariad Pharmaceuticals, Inc.; Astellas Pharma; Tesaro, Inc.; Euclises Phamaceuticals, Inc.; Grant/Research Support: Takeda/Ariad Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Co; Pfizer, Inc.; Xcovery Holding Co LLC; Adaptimmune Therapeutics; AbbVie; Novartis Pharmaceuticals Corp; Genentech, Inc.

Jonathan W. Riess, MD, MSJonathan W. Riess, MD, MS, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Ariad Pharmaceuticals, Inc; AbbVie; Medtronic Inc.
Mark A. Socinski, MDMark A.  Socinski, MD, reported a financial interest/relationship or affiliation in the form of Speakers' bureau, Genentech, Inc; Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Celgene Corp; Contracted research, Genentech, Inc; Pfizer, Inc; AbbVie
Heather Wakelee, MDHeather Wakelee, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Peregrine Pharmaceuticals, Inc; ACEA; Pfizer, Inc; Helsinn Therapeutics (US) Inc; Genentech, Inc; Research grant, Clovis Oncology; Exelixis, Inc; AstraZeneca Pharmaceuticals LP; Genentech/Roche; Bristol-Myers Squibb Co; Gilead; Novartis Pharmaceuticals Corp; Xcovery, Pfizer, Inc; Celgene Corp; Pharmacyclics, Inc; Eli Lilly and Co.
Jared Weiss, MDJared Weiss, MD    Jared Weiss, MD, reported a financial interest/relationship or affiliation in the form of Research grant, AstraZeneca Pharmaceuticals LP; Astellas Pharma US, Inc; Merck & Co, Inc; Pfizer, Inc; Novartis Pharmaceuticals Corp; Celgene Corp; Received income in any amount from, AstraZeneca Pharmaceuticals LP; EMD Serono, Inc.


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

There is no fee for this educational activity.

This activity is provided by:

AXIS 1571

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Attendance

Accreditation Period

Course opens: 
08/14/2017
Course expires: 
12/28/2018

Price

Cost:
$0.00
Please login or register to take this course.